Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label Phase 1/2 (Safety Lead-in) Study of Trans Sodium Crocetinate (TSC) With Concomitant Treatment of Fractionated Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Patients to Evaluate Safety and Efficacy.

Next Previous
Trial Profile

Open-label Phase 1/2 (Safety Lead-in) Study of Trans Sodium Crocetinate (TSC) With Concomitant Treatment of Fractionated Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Patients to Evaluate Safety and Efficacy.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Transcrocetinate sodium (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Diffusion Pharmaceuticals

    • Most Recent Events

    • 15 Nov 2018 According to a Diffusion Pharmaceuticals media release, results from this study will be presented at the 2018 Annual Meeting of the Society for NeuroOncology (SNO) (Nov 2018).
    • 01 Jun 2018 NCT mention trial as phase 1/2 trial,whereas MR-9241881 mention is as phase 2 study kept phase as per NCT
    • 08 Feb 2017 According to Diffusion Pharmaceuticals media release, data from this study has been published in the print edition of the peer-reviewed Journal of Neurosurgery.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top